Congress trade9 different filers disclosed LLY within 90 days. Disclosed 276 days after the transaction; reported as an official range, not an exact amount.
Loading…
Eli Lilly
LLY · NYSE · Pharmaceuticals
LLY · NYSE · Pharmaceuticals
Diabetes, obesity and cancer medicines.
Last close, Oct 1, 2026
$1,149.85
Adjusted for splits and dividends
Last 12 months
+39.3%
S&P 500 +14.3% over the same dates
Market value
$1.08T
Last close × shares outstanding
Bets against the stock: 7.52M shares sold short (0.8% of shares outstanding), -4.7% vs the previous count, 3.4 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
3 sales
$16M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$65.2B
+44.7% vs the year before
Net income, fiscal 2025
$20.6B
As reported in the annual filing
Shares outstanding
941M
As of Aug 3, 2026
In fiscal 2025 the company spent $4.11B buying back its own shares and $5.38B on dividends. Cash actually paid, from its cash-flow statement.
9 different filers disclosed LLY within 90 days. Disclosed 276 days after the transaction; reported as an official range, not an exact amount.
Officer sold ~$7.64M of Eli Lilly
Scheduled in advanceA top manager at Eli Lilly told the SEC they plan to sell $7.64M of Eli Lilly shares around Aug 17, 2026. The shares did not come from their pay.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
132 certified in FY2026 Q3, vs 310 a year earlier. 475 positions in total, median offered wage $136K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
15 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
LILLY ENDOWMENT, INC.
Schedule 13G: passive · filed Jul 23, 2026 · 90.4M shares
Vanguard Capital Management
Schedule 13G: passive · filed May 1, 2026 · 61.3M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $825.42 on Oct 1, 2025 to $1,149.85 on Oct 1, 2026 (+39.3%). Disclosed trades in the last 12 months: 0 insider purchases, 362 insider sales (5 under pre-arranged plans), 10 Congress purchases, 14 Congress sales.
Short sale volume: 47.1% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 39.0%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 997 shares (about $1.12M) were not delivered on time for settlement on Sep 9, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.